These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 392176)

  • 41. Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure.
    Ataka K; Maruyama H; Neichi T; Miyazaki J; Gejyo F
    Am J Nephrol; 2003; 23(5):315-23. PubMed ID: 12915775
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erythropoiesis in chronic renal disease.
    Zucker S; Lysik RM; Mohammad G
    J Lab Clin Med; 1976 Oct; 88(4):528-35. PubMed ID: 965807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients.
    Abraham PA; Opsahl JA; Rachael KM; Asinger R; Halstenson CE
    Am J Nephrol; 1990; 10(2):128-36. PubMed ID: 2349956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects.
    Nissenson AR; Nimer SD; Wolcott DL
    Ann Intern Med; 1991 Mar; 114(5):402-16. PubMed ID: 1992884
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erythropoietin and improvement of anemia in long-term hemodialysis patients.
    Dukanovic L; Clemons GK; Ikonomovski J; Biljanovic-Paunović L; Pavlović-Kentera V
    Acta Med Iugosl; 1991; 45(2):151-60. PubMed ID: 1887810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination].
    Wiecek A; Kokot F; Grzeszczak W; Klin M
    Pol Tyg Lek; 1990 Sep 17-24; 45(38-39):782-6. PubMed ID: 2095546
    [TBL] [Abstract][Full Text] [Related]  

  • 48. End-stage renal disease following polycythemia vera: in vitro and in vivo response of erythroid progenitors to erythropoietin and effects of sera on normal erythropoiesis.
    Shih LY; Huang JY
    Nephron; 1998; 79(2):142-7. PubMed ID: 9647492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of recombinant human erythropoietin (rHu-EPO) on anemia and selected biochemical parameters in patients in the pre-dialysis period].
    Sułowicz W; Drozdz M; Hanicki Z; Kraśniak A; Kuźniewski M
    Przegl Lek; 1992; 49(1-2):50-3. PubMed ID: 1455007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erythropoietin and anemia in chronic renal failure.
    Pavlović-Kentera V; Clemons GK; Djukanović L; Biljanović-Paunovic L
    Exp Hematol; 1987 Aug; 15(7):785-9. PubMed ID: 3609182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of erythroid inhibiting factors (EIF) in patients with anemia of chronic renal failure.
    Radtke HW; Rege AB; LaMarche M; Fisher JW
    Proc Clin Dial Transplant Forum; 1979; 9():179-83. PubMed ID: 552040
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of hemodialysis and recombinant human erythropoietin on determinants of blood viscosity.
    Shand BI; Buttimore AL; Lynn KL; Bailey RR; Robson RA
    Ren Fail; 1994; 16(3):407-13. PubMed ID: 8059023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Recent findings on the pathogenesis and therapy of anemia in chronic kidney failure].
    Moccia F; Morra L; Gurreri G
    Recenti Prog Med; 1992 Oct; 83(10):572-6. PubMed ID: 1462041
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical effect of recombinant human erythropoietin on anemia associated with chronic renal failure. A multi-institutional study in Japan.
    Akizawa T; Koshikawa S; Takaku F; Urabe A; Akiyama N; Mimura N; Otsubo O; Nihei H; Suzuki Y; Kawaguchi Y
    Int J Artif Organs; 1988 Sep; 11(5):343-50. PubMed ID: 3056862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sustained negative feedback between haematocrit and serum erythropoietin concentration in end-stage renal failure.
    Erbes PM; Radtke HW; Schoeppe W; Koch KM
    Proc Eur Dial Transplant Assoc; 1978; 15():442-8. PubMed ID: 740677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients.
    Kuriyama S; Hopp L; Yoshida H; Hikita M; Tomonari H; Hashimoto T; Sakai O
    Am J Hypertens; 1996 May; 9(5):426-31. PubMed ID: 8735172
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Erythropoietin inhibitor in plasma from patients with chronic renal failure.
    Moriyama Y; Saito H; Kinoshita Y
    Haematologia (Budap); 1970; 4(1):15-20. PubMed ID: 5522355
    [No Abstract]   [Full Text] [Related]  

  • 59. The treatment of anemia with low-dose recombinant human erythropoietin.
    Aronoff GR; Duff DR; Sloan RS; Brier ME; Maurice B; Erickson B; Golper TA
    Am J Nephrol; 1990; 10 Suppl 2():40-3. PubMed ID: 2260617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Serum immunoreactive erythropoietin in patients with end stage renal disease.
    Gimenez LF; Watson AJ; Spivak JL
    Prog Clin Biol Res; 1990; 352():493-504. PubMed ID: 2402519
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.